Eugit Therapeutics
YC S22Enabling Tissue Targeting of Therapies
San Francisco, CA, USA; South San Francisco, CA, USAFounded 20222 employeeswww.eugittx.com
Team
2
Founded
2022
About
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Tags
No open roles at this time.
Similar Healthcare startups
Guardian Bio
Dendritic cell-based platform for cancer therapy
BiotechHealthcareTherapeutics
Open Jobs —
Team 2
Founded 2022
Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
BiotechTherapeuticsDrug discovery
Open Jobs —
Team 2
Founded 2022
Indee Labs
Enabling T cell immunotherapy discovery, development and manufacturing
Gene TherapyMicrofluidicsCell Therapy
Open Jobs —
Team 5
Founded 2016
AT
Altay Therapeutics
Altay develops disease-modifying therapies targeting transcription…
AI-powered Drug DiscoveryBiotechTherapeutics
Open Jobs —
Team 6
Founded 2020